FeesSafety
Pluang+

Atebimetinib shows strong potential as a combination therapy backbone for pancreatic cancer in new Immuneering data

Market News
18 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Atebimetinib shows strong potential as a combination therapy backbone for pancreatic cancer in new Immuneering data

Immuneering Corporation presented new preclinical and clinical data showing that atebimetinib, a MEK inhibitor, has broad potential as a backbone for combination therapies in pancreatic cancer. Phase 2 results showed long survival and good tolerability when combined with chemotherapy, and ongoing Phase 3 trials are evaluating this further. The drug demonstrated synergistic effects with targeted agents against KRAS mutations and other pathways, suggesting it could be used across multiple patient subsets and lines of therapy. This supports Immuneering's strategy to develop atebimetinib as a central treatment option in pancreatic cancer and possibly other MAPK-driven cancers.

Immuneering's atebimetinib data presentation offers context for readers tracking health-sector stocks. For readers following health-sector equities, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced US health stocks, 55 rose and 86 fell. Notable movers include Liquidia Corporation (LQDA) at USD 55.19 with a 1-day change of -2.71% and 100% sell order activity, Recursion Pharmaceuticals (RXRX) at USD 2.79 up 2.57% with 87% sell orders, and Inovio Pharmaceuticals (INO) at USD 1.59 down 2.45% with 78% sell orders. Typical hold times range from 5 to 41 days on Pluang.

More News

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
43 minutes ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
1 hour ago
SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse, a B2B automotive software marketplace founded by General Motors, Magna, and Wipro, was honored with a CES Innovation Award 2027 in the Enterprise Tech category. The platform uses AI and standardized technical data to help automakers and supp...

Others
Bullish
1 hour ago
Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures, a Silicon Valley venture firm, has closed its first fund at $12.24 million to invest in early-stage B2B AI and SaaS startups from programs like Y Combinator and Berkeley SkyDeck before their Demo Days. The fund has already backe...

Others
Bullish
1 hour ago
Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac announced that CEO Paul Martingell and CFO Habib Ramdani will present and hold a Q&A session at the Jefferies Global Healthcare Conference in London on November 18, 2026. Investors and interested parties can watch the live webcast on Virbac's ...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App